Where is Breakthrough Diagnostics located?

Breakthrough Diagnostics is headquartered in New York City, United States.

Where does Breakthrough Diagnostics rank among its competitors?

Breakthrough Diagnostics ranks 20th amongst 47 active competitors, of which 19 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was ALZpath, which secured $8.41M in Jul, 2026.

Who are the top competitors of Breakthrough Diagnostics?

Breakthrough Diagnostics' top competitors include NeuroDex, C₂N Diagnostics and ALZpath. Among them, ALZpath secured the most recent funding round in July, 2026.

Breakthrough Diagnostics - 2026 Company Profile & Competitors

Company Details

Developer of blood test for detection of Alzheimer's disease. The company offers Lymphocyte Proliferation(LymPro Test) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to detect alzheimers disease.

Key Metrics

Location

New York City, United States

Stage

Unfunded

Ranked

20^th among 47 active competitors

Investment & Acquisitions

Durin Technologies

Similar Companies

NeuroDex & 60 more

View Breakthrough Diagnostics' full profile

Breakthrough Diagnostics has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Breakthrough Diagnostics include NeuroDex, C₂N Diagnostics and ALZpath. Here is the list of Top 10 competitors of Breakthrough Diagnostics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	NeuroDex 2018, Natick (United States), Seed	Manufacturer of diagnostic tools for Alzheimer's disease	$1.36M	ICV, Military Health & 1 others	59/100
2nd	C₂N Diagnostics 2007, St. Louis (United States), Series B	Developer of diagnostics and therapies for Alzheimer's disease	$35M	Eisai, Samsung Venture Investment & 6 others	58/100
3rd	ALZpath 2020, Carlsbad (United States), Series A	Developer of diagnostic solutions for Alzheimer's Disease	$8.41M	Stead Impact Ventures, Alzheimer's Drug Discovery	55/100
4th	Amydis Diagnostics 2013, San Diego (United States), Series A	Developer of diagnostics test for detection of Alzheimer's disease	$8.69M	NIA, Springboard Enterprises & 4 others	53/100
5th	Todos Medical 2009, Rehovot (Israel), Public	Developer of in vitro diagnostics for the detection of cancer and neurodegenerative disorders	-	Lincoln Park Capital, Yozma & 2 others	45/100
6th	DiamiR 2009, Monmouth Junction (United States), Funding Raised	Developer of minimally invasive diagnostic tests	-	NIA, HHS	43/100
7th	ADmit Therapeutics 2017, Barcelona (Spain), Series A	Provider of diagnostic services for early detection of Alzheimer's disease	$12.9M	Ship2B, Clave & 13 others	42/100
8th	Lucent Diagnostics 2023, Billerica (United States), Unfunded	Developer of a biomarker blood test for the diagnosis of Alzheimer's disease	-	-	40/100
9th	Veravas 2017, Oakdale (United States), Series A	Provider of platform to manage sample preparation and diagnostic solutions	$25M	SeedFunders	38/100
10th	bioLOCKEY Healthworks 2023, Bengaluru (India), Seed	Developer of point-of-care diagnostics and novel biologics by Nanobody discovery platform	$478K	Pfizer, Pfizer INDovation & 7 others	37/100
20th	Breakthrough Diagnostics New York City (United States), Unfunded	Developer of blood test for the detection of Alzheimer's disease	-	-	28/100